would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Immunity in the Elderly (R01).  
Date: July 9–10, 2018.  
Time: 9:00 a.m. to 5:00 p.m.  
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health LD30, 5601 Fishers Lane, Rockville, MD 20892.  
Contact Person: Julio Aliberti, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIADDK/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 301–761–7322, aliberti@niaid.nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Maintaining Immunity after Allergy and Infectious Diseases Special Emphasis Panel; Immunity in the Elderly (R01).  
Date: July 9–10, 2018.  
Time: 9:00 a.m. to 5:00 p.m.  
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health LD30, 5601 Fishers Lane, Rockville, MD 20892.  
Contact Person: Julio Aliberti, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIADDK/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 301–761–7322, aliberti@niaid.nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Immunity in the Elderly (U01).  
Date: July 11–12, 2018.  
Time: 8:30 a.m. to 2:00 p.m.  
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892.  
Contact Person: Geetanjali Bansal, Ph.D., Scientific Reviewer Officer, Scientific Review Program, Division of Extramural Activities, Room 3049, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892–9834, (240) 669–5073, geetanjali.bansal@nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID INVESTIGATOR INITIATED PROGRAM PROJECT (P01).  
Date: July 11, 2018.  
Time: 1:00 p.m. to 5:00 p.m.  
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892.  
(Telephone Conference Call).

Contact Person: Raymond R. Schleef, Ph.D., Senior Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E01, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5019, schleefrr@niaid.nih.gov.  
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)


Natasha M. Copeland,  
Program Analyst, Office of Federal Advisory Committee Policy.  
[FR Doc. 2018–13138 Filed 6–18–18; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration  

Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on August 8, 2018, from 9:00 a.m. EDT to 5:00 p.m. EDT.

The board will meet in closed-session via web conference on August 8, 2018, from 9:00 a.m. EDT to 5:00 p.m. EDT to discuss the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair specimens). Therefore, the meeting is closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d).

Meeting registration information can be completed at http://snacregister.samhsa.gov/MeetingList.aspx. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, http://www.samhsa.gov/about-us/advisory-councils/drug-testing-advisory-board-dtab or by contacting the Designated Federal Officer, CAPT Sean J. Belouin, USPHS.

Committee Name: Substance Abuse and Mental Health Services Administration’s Drug Testing Advisory Board.

Dates/Time/Type: August 8, 2018, from 9:00 a.m. to 5:00 p.m. EDT: CLOSED.

Place: Web Conference.

Contact: CAPT Sean J. Belouin, USPHS, Senior Pharmacology and Regulatory Policy Advisor, Division of Workplace Programs, 5600 Fishers Lane, Room 16N06D, Rockville, Maryland 20857, Telephone: (240) 276–2600, Email: sean.belouin@samhsa.hhs.gov.

Carlos Castillo,  
Committee Management Officer, SAMHSA.  
[FR Doc. 2018–13131 Filed 6–18–18; 8:45 am]